Bacterial meningitis in children

TL;DR: The changing epidemiology of bacterial meningitis in the United States and throughout the world is described by reviewing the global changes in etiological agents followed by specific microorganism data on the impact of the development and widespread use of conjugate vaccines.

TL;DR: Corticosteroids significantly reduced hearing loss and neurological sequelae, but did not reduce overall mortality, and data support the use of corticosteroid in patients with bacterial meningitis.

TL;DR: The nature of the host immune response to this type of infection and the balance between clearance of the pathogen and avoidance of damage to host tissues are discussed.

TL;DR: A succinct overview of the current state‐of‐play in BBB research is provided and novel findings into BBB regulation in homeostatic regulation of the brain are summarized.

TL;DR: The pathophysiological events that are believed to contribute to adverse outcome from bacterial meningitis include alteration of cerebral capillary endothelial cells that comprise the blood-brain barrier, cytotoxic and vasogenic cerebral edema, loss of autoregulation, and increased intracranial pressure as discussed by the authors.

TL;DR: Although patients with effusion were more likely to have neurologic abnormalities both at the time of admission and at completion of therapy, and were morelikely to have seizures during the course of treatment, there was no greater incidence of seizures, hearing loss, neurologic deficits, or developmental delay on longterm follow-up in patients with Effusion.

TL;DR: GBS capsular polysaccharide (CPSC) is a major target of antibody-mediated immunity as discussed by the authors, and the CPS-protein conjugate vaccines are safe, well-tolerant and immunogenic in healthy adults.